132 related articles for article (PubMed ID: 19422479)
1. Effects of ursodeoxycholic acid in combination with vitamin E on adipokines and apoptosis in patients with nonalcoholic steatohepatitis.
Balmer ML; Siegrist K; Zimmermann A; Dufour JF
Liver Int; 2009 Sep; 29(8):1184-8. PubMed ID: 19422479
[TBL] [Abstract][Full Text] [Related]
2. Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin e in nonalcoholic steatohepatitis.
Dufour JF; Oneta CM; Gonvers JJ; Bihl F; Cerny A; Cereda JM; Zala JF; Helbling B; Steuerwald M; Zimmermann A;
Clin Gastroenterol Hepatol; 2006 Dec; 4(12):1537-43. PubMed ID: 17162245
[TBL] [Abstract][Full Text] [Related]
3. Adipohormones as prognostric markers in patients with nonalcoholic steatohepatitis (NASH).
Krawczyk K; Szczesniak P; Kumor A; Jasinska A; Omulecka A; Pietruczuk M; Orszulak-Michalak D; Sporny S; Malecka-Panas E
J Physiol Pharmacol; 2009 Oct; 60 Suppl 3():71-5. PubMed ID: 19996485
[TBL] [Abstract][Full Text] [Related]
4. Management of fatty liver disease with vitamin E and C compared to ursodeoxycholic acid treatment.
Ersöz G; Günşar F; Karasu Z; Akay S; Batur Y; Akarca US
Turk J Gastroenterol; 2005 Sep; 16(3):124-8. PubMed ID: 16245220
[TBL] [Abstract][Full Text] [Related]
5. Ursodeoxycholic acid with vitamin E in patients with nonalcoholic steatohepatitis: long-term results.
Pietu F; Guillaud O; Walter T; Vallin M; Hervieu V; Scoazec JY; Dumortier J
Clin Res Hepatol Gastroenterol; 2012 Apr; 36(2):146-55. PubMed ID: 22154224
[TBL] [Abstract][Full Text] [Related]
6. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial.
Lindor KD; Kowdley KV; Heathcote EJ; Harrison ME; Jorgensen R; Angulo P; Lymp JF; Burgart L; Colin P
Hepatology; 2004 Mar; 39(3):770-8. PubMed ID: 14999696
[TBL] [Abstract][Full Text] [Related]
7. Adipokine serum levels are related to liver histology in severely obese patients undergoing bariatric surgery.
Argentou M; Tiniakos DG; Karanikolas M; Melachrinou M; Makri MG; Kittas C; Kalfarentzos F
Obes Surg; 2009 Sep; 19(9):1313-23. PubMed ID: 19693638
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia.
Hyogo H; Tazuma S; Arihiro K; Iwamoto K; Nabeshima Y; Inoue M; Ishitobi T; Nonaka M; Chayama K
Metabolism; 2008 Dec; 57(12):1711-8. PubMed ID: 19013295
[TBL] [Abstract][Full Text] [Related]
9. [UDCA in the treatment of nonalcoholic fatty liver disease].
Grigor'eva IN
Eksp Klin Gastroenterol; 2011; (11):79-85. PubMed ID: 22629725
[TBL] [Abstract][Full Text] [Related]
10. A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis.
Sanyal AJ; Mofrad PS; Contos MJ; Sargeant C; Luketic VA; Sterling RK; Stravitz RT; Shiffman ML; Clore J; Mills AS
Clin Gastroenterol Hepatol; 2004 Dec; 2(12):1107-15. PubMed ID: 15625656
[TBL] [Abstract][Full Text] [Related]
11. Changes in serum adipokine levels during pioglitazone treatment for nonalcoholic steatohepatitis: relationship to histological improvement.
Lutchman G; Promrat K; Kleiner DE; Heller T; Ghany MG; Yanovski JA; Liang TJ; Hoofnagle JH
Clin Gastroenterol Hepatol; 2006 Aug; 4(8):1048-52. PubMed ID: 16814613
[TBL] [Abstract][Full Text] [Related]
12. Ursodeoxycholyl lysophosphatidylethanolamide improves steatosis and inflammation in murine models of nonalcoholic fatty liver disease.
Pathil A; Mueller J; Warth A; Chamulitrat W; Stremmel W
Hepatology; 2012 May; 55(5):1369-78. PubMed ID: 22183915
[TBL] [Abstract][Full Text] [Related]
13. Adipokines in NASH: postprandial lipid metabolism as a link between adiponectin and liver disease.
Musso G; Gambino R; Durazzo M; Biroli G; Carello M; Fagà E; Pacini G; De Michieli F; Rabbione L; Premoli A; Cassader M; Pagano G
Hepatology; 2005 Nov; 42(5):1175-83. PubMed ID: 16231364
[TBL] [Abstract][Full Text] [Related]
14. Serum adipokine levels in chronic liver diseases: association of resistin levels with fibrosis severity.
Tsochatzis E; Papatheodoridis GV; Hadziyannis E; Georgiou A; Kafiri G; Tiniakos DG; Manesis EK; Archimandritis AJ
Scand J Gastroenterol; 2008; 43(9):1128-36. PubMed ID: 18609175
[TBL] [Abstract][Full Text] [Related]
15. [UDCA in the treatment of nonalcoholic fatty liver disease].
Grigor'eva IN
Eksp Klin Gastroenterol; 2011; (9):125-31. PubMed ID: 22629789
[TBL] [Abstract][Full Text] [Related]
16. A novel diagnostic biomarker panel for obesity-related nonalcoholic steatohepatitis (NASH).
Younossi ZM; Jarrar M; Nugent C; Randhawa M; Afendy M; Stepanova M; Rafiq N; Goodman Z; Chandhoke V; Baranova A
Obes Surg; 2008 Nov; 18(11):1430-7. PubMed ID: 18500507
[TBL] [Abstract][Full Text] [Related]
17. High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial.
Leuschner UF; Lindenthal B; Herrmann G; Arnold JC; Rössle M; Cordes HJ; Zeuzem S; Hein J; Berg T;
Hepatology; 2010 Aug; 52(2):472-9. PubMed ID: 20683947
[TBL] [Abstract][Full Text] [Related]
18. Vitamin E has a beneficial effect on nonalcoholic fatty liver disease: a meta-analysis of randomized controlled trials.
Sato K; Gosho M; Yamamoto T; Kobayashi Y; Ishii N; Ohashi T; Nakade Y; Ito K; Fukuzawa Y; Yoneda M
Nutrition; 2015; 31(7-8):923-30. PubMed ID: 26059365
[TBL] [Abstract][Full Text] [Related]
19. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease.
Bugianesi E; Gentilcore E; Manini R; Natale S; Vanni E; Villanova N; David E; Rizzetto M; Marchesini G
Am J Gastroenterol; 2005 May; 100(5):1082-90. PubMed ID: 15842582
[TBL] [Abstract][Full Text] [Related]
20. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis.
Harrison SA; Torgerson S; Hayashi P; Ward J; Schenker S
Am J Gastroenterol; 2003 Nov; 98(11):2485-90. PubMed ID: 14638353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
